FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217791888> ?p ?o ?g. }

• W3217791888 endingPage "4761" @default.
• W3217791888 startingPage "4761" @default.
• W3217791888 abstract "Abstract Background Research has demonstrated that histone deacetylase (HDAC) is overexpressed in plasma cells. Panobinostat was the first HDAC inhibitor (HDACi) approved by FDA for the treatment of patients with relapse and refractory multiple myeloma (RRMM) in 2015. Chidamide is an oral subtype-selective HDACi, which was independently developed in China and approved as peripheral T-cell lymphoma. Preclinical findings have demonstrated the anti-myeloma activities of chidamide in vitro and in vivo. Currently, patients are recommended to take bortezomib and/or lenalidomide in first line treatment and might become less sensitive or resistant when disease progressed. Choices are limited for these patients as not all the new agents (i.e., second generation of PIs/ IMiDs, monoclonal antibody, et al.) were covered by insurance in China, which calls for more efficient and economical options. Here we report the initial efficacy and safety of this prospective, phase IIa, multicenter clinical trial with the chidamide based oral quadruplet regimen in patients with RRMM (ChiCTR2000035100). Methods The TC2D regimen (thalidomide 100mg on days 1-28, chidamide 5mg on days 1-24, cyclophosphamide 50mg on days 1-24 and dexamethasone 20mg on days 1,8,15 and 22) was administered to patients with RRMM of a 28-day cycle. In this trial, evaluation of overall response rate (ORR) was based on patients whose response ≥MR and clinical beneficial rate (CBR) was calculated in patients completed at least 3 cycles of TC2D regimen and reached ≥SD in this trial. Results A total of 32 patients were enrolled as of June 30, 2021, with a median age of 63.5 years (range 49-74). iFISH detected high-risk cytogenetics (defined by the presence of del (17p) or p53 mutation, t (4:14), t (14:16), t (14:20), amp (1q)) in 23 patients, and 82% (19/23) of which had unfavorable cytogenetics. All patients were exposed to at least one kind of PIs and/or IMiDs and 75% were double refractory to bortezomib and lenalidomide. 18 patients received 1-3 prior lines and 43% (14/32) were heavily pre-treated (&gt;3 lines). The median number of cycles completed was 3 (range 1-15) and 59% (19/32) patients completed ≥ 3cycles at the cut-off date (Table 1). With the median follow-up of 6 months (range 0.7-19.5), the median progression free survival (PFS) was 3.3 months and the 6-mon PFS rate was 27.5% (Fig1a). Median overall survival (OS) has not reached yet, 6-mon survival rate was 82%, and the estimated 12-month survival rate was 65% (Fig 1b). Study end points were death (8 cases, 25%) and disease progression (24 cases, 75%). Patients who received ≥3 cycles of treatment had a superior median PFS (3.8 vs 1.4 months, P=0.01) than &lt; 3 cycles. Of the 28 patients whose follow-up time more than 3 months, ORR was 25% and CBR was 46.4%, respectively. Better CBR (56.3% vs. 33.3%) and ORR (31.3% vs. 16.7%) were observed in patients who received less than 3 prior lines of therapy, although with no significant statistical difference. Stratified analysis of PFS showed no significant differences in sex, age, clinical classification, cytogenetic risk, prognosis score (DS and ISS staging system), and the status of ASCT. Stratified analysis of OS showed similar results to those associated with PFS. Grade 3/4 adverse events were mainly hematological toxicity (neutropenia 28%, anemia 34%, thrombocytopenia 15.6%), which could be tolerated. Fatigue was reported in 68.8% (22/32) of the patients. The incidence of all-cause infection was 37.5% (12/32). There were no treatment related deaths observed. Conclusions To our knowledge, this is the first report of chidamide-based oral quadruplet regimen for patients with RRMM. The preliminary results suggested excellent efficacy and relatively high safety, and different groups of patients could benefit from treatment with this regimen. A longer treatment period may strengthen this effect. The most common adverse events were hematological toxicity which could be controlled. As we known, choices of treatment are also influenced by physical and emotional impact of hospitalization or frequent hospital visits, which reflects the patient's ability to continue their treatment and quality of life. Hospitalization and intravenous fluids are not involved in this oral quadruplet treatment, which bring far more convenience and could be a cost-effective alternative for patients with RRMM. Updated results will be presented at the following trial. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare." @default.
• W3217791888 created "2021-12-06" @default.
• W3217791888 creator A5005286554 @default.
• W3217791888 creator A5009815987 @default.
• W3217791888 creator A5015789291 @default.
• W3217791888 creator A5017849879 @default.
• W3217791888 creator A5030639018 @default.
• W3217791888 creator A5036246435 @default.
• W3217791888 creator A5044490554 @default.
• W3217791888 creator A5044547848 @default.
• W3217791888 creator A5064842058 @default.
• W3217791888 creator A5069504531 @default.
• W3217791888 creator A5076516025 @default.
• W3217791888 creator A5089465933 @default.
• W3217791888 creator A5089639451 @default.
• W3217791888 creator A5089986341 @default.
• W3217791888 creator A5090013547 @default.
• W3217791888 creator A5090257305 @default.
• W3217791888 date "2021-11-05" @default.
• W3217791888 modified "2023-09-27" @default.
• W3217791888 title "Efficacy and Safety of Chidamide Combined with Thalidomide, Cyclophosphamide, and Dexamethasone (TC2D) As a Novel Oral Quadruplet Regimen for the Treatment of Relapsed/Refractory Multiple Myeloma: Initial Results of a Phase IIa, Multicenter Clinical Trial" @default.
• W3217791888 doi "https://doi.org/10.1182/blood-2021-149188" @default.
• W3217791888 hasPublicationYear "2021" @default.
• W3217791888 type Work @default.
• W3217791888 sameAs 3217791888 @default.
• W3217791888 citedByCount "0" @default.
• W3217791888 crossrefType "journal-article" @default.
• W3217791888 hasAuthorship W3217791888A5005286554 @default.
• W3217791888 hasAuthorship W3217791888A5009815987 @default.
• W3217791888 hasAuthorship W3217791888A5015789291 @default.
• W3217791888 hasAuthorship W3217791888A5017849879 @default.
• W3217791888 hasAuthorship W3217791888A5030639018 @default.
• W3217791888 hasAuthorship W3217791888A5036246435 @default.
• W3217791888 hasAuthorship W3217791888A5044490554 @default.
• W3217791888 hasAuthorship W3217791888A5044547848 @default.
• W3217791888 hasAuthorship W3217791888A5064842058 @default.
• W3217791888 hasAuthorship W3217791888A5069504531 @default.
• W3217791888 hasAuthorship W3217791888A5076516025 @default.
• W3217791888 hasAuthorship W3217791888A5089465933 @default.
• W3217791888 hasAuthorship W3217791888A5089639451 @default.
• W3217791888 hasAuthorship W3217791888A5089986341 @default.
• W3217791888 hasAuthorship W3217791888A5090013547 @default.
• W3217791888 hasAuthorship W3217791888A5090257305 @default.
• W3217791888 hasConcept C126322002 @default.
• W3217791888 hasConcept C143998085 @default.
• W3217791888 hasConcept C2776063141 @default.
• W3217791888 hasConcept C2776364478 @default.
• W3217791888 hasConcept C2776694085 @default.
• W3217791888 hasConcept C2776755627 @default.
• W3217791888 hasConcept C2777478702 @default.
• W3217791888 hasConcept C2779609412 @default.
• W3217791888 hasConcept C2780401358 @default.
• W3217791888 hasConcept C2781413609 @default.
• W3217791888 hasConcept C31760486 @default.
• W3217791888 hasConcept C535046627 @default.
• W3217791888 hasConcept C71924100 @default.
• W3217791888 hasConcept C98274493 @default.
• W3217791888 hasConceptScore W3217791888C126322002 @default.
• W3217791888 hasConceptScore W3217791888C143998085 @default.
• W3217791888 hasConceptScore W3217791888C2776063141 @default.
• W3217791888 hasConceptScore W3217791888C2776364478 @default.
• W3217791888 hasConceptScore W3217791888C2776694085 @default.
• W3217791888 hasConceptScore W3217791888C2776755627 @default.
• W3217791888 hasConceptScore W3217791888C2777478702 @default.
• W3217791888 hasConceptScore W3217791888C2779609412 @default.
• W3217791888 hasConceptScore W3217791888C2780401358 @default.
• W3217791888 hasConceptScore W3217791888C2781413609 @default.
• W3217791888 hasConceptScore W3217791888C31760486 @default.
• W3217791888 hasConceptScore W3217791888C535046627 @default.
• W3217791888 hasConceptScore W3217791888C71924100 @default.
• W3217791888 hasConceptScore W3217791888C98274493 @default.
• W3217791888 hasIssue "Supplement 1" @default.
• W3217791888 hasLocation W32177918881 @default.
• W3217791888 hasOpenAccess W3217791888 @default.
• W3217791888 hasPrimaryLocation W32177918881 @default.
• W3217791888 hasRelatedWork W1520916227 @default.
• W3217791888 hasRelatedWork W1967461244 @default.
• W3217791888 hasRelatedWork W1999964913 @default.
• W3217791888 hasRelatedWork W2009883886 @default.
• W3217791888 hasRelatedWork W2013163224 @default.
• W3217791888 hasRelatedWork W2751497063 @default.
• W3217791888 hasRelatedWork W2980910443 @default.
• W3217791888 hasRelatedWork W3127479238 @default.
• W3217791888 hasRelatedWork W4225390146 @default.
• W3217791888 hasRelatedWork W2182322203 @default.
• W3217791888 hasVolume "138" @default.
• W3217791888 isParatext "false" @default.
• W3217791888 isRetracted "false" @default.
• W3217791888 magId "3217791888" @default.
• W3217791888 workType "article" @default.